Clonal Cytopenia of Undetermined SignificancePhase 2NCT05030441
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
A Phase 2 study testing Ivosidenib in people with Clonal Cytopenia of Undetermined Significance, run by Washington University School of Medicine at 2 sites in United States.
Trial summary
This is an open-label, multicenter study exploring the efficacy of ivosidenib in patients with clonal cytopenia of undetermined significance (CCUS) with mutations in IDH1. The purpose is to establish proof of principle that ivosidenib is well-tolerated and potentially efficacious in improving blood count abnormalities… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Clonal Cytopenia of Undetermined Significance
- What is being tested?
- Ivosidenib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 2 sitesUnited States
- Study dates
- 1 Apr 2022to 31 Jan 2030
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Unexplained cytopenia for at least 6 months. Cytopenia is defined as the presence of ≥1 blood count indexes below the following thresholds:
- Hgb <10 g/dL
- ANC <1.8 × 10^9/L
- Platelets <100 × 10^9/L
- IDH1 gene mutation (R132) confirmed by droplet digital PCR (ddPCR) testing, at a frequency > 2%. This will be performed locally and confirmed at Washington University.
- At least 18 years of age.
Show all 13Show fewer
- ECOG performance status 0-2
- Adequate organ function as defined below:
- AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
- Serum total bilirubin < 1.5 x IULN (an upper limit of bilirubin 5mg/dL is acceptable if it can be attributed to Gilbert's syndrome or erythropoiesis)
- Serum creatinine < 2 x IULN or creatinine clearance > 50 mL/min by Cockcroft-Gault glomerular filtration rate estimation
- The effects of ivosidenib on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (defined in Section 5.5) prior to study entry, for the duration of study participation, and for 90 days after the last dose of ivosidenib. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and for 90 days after the last dose of ivosidenib.
- Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Who cannot join
- Indication of hematologic disease by bone marrow biopsy within 6 months of study entry.
- Evidence of disease progression from time of bone marrow biopsy to enrollment based on investigator review of symptoms and complete blood counts
- Active malignancy (defined as > 1 cm disease on most recent CT scan in the past 6 months).
- Currently receiving therapy for solid tumor malignancy.
- Currently receiving any other investigational agents.
- Known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.
Show all 12Show fewer
- A history of allergic reactions attributed to compounds of similar chemical or biologic composition to ivosidenib or other agents used in the study.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 72 hours of study entry.
- Heartrate corrected QT interval (QTc) > 450 msec or with other factors that increase the risk of QT prolongation or arrhythmic events (e.g. heart failure, hypokalemia, family history of long QT interval syndrome).
- Known medical history of progressive multifocal leukoencephalopathy (PML).
- Currently taking medications known to be CYP3A4 strong inducers and sensitive substrates.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Cleveland Clinic - Case Comprehensive Cancer Center
Cleveland, Ohio, 44195
Washington University School of Medicine
St Louis, Missouri, 63110
About this study
Official title: A Pilot Study of Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
This is an open-label, multicenter study exploring the efficacy of ivosidenib in patients with clonal cytopenia of undetermined significance (CCUS) with mutations in IDH1. The purpose is to establish proof of principle that ivosidenib is well-tolerated and potentially efficacious in improving blood count abnormalities in these patients.
The study will also be offered in a decentralized, remote structure to patients.
- Being tested
- Ivosidenib
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IvosidenibDrug
Also called TIBSOVO
. Patients should take ivosidenib at approximately the same time every day, with or without food, but should be instructed to avoid a high-fat meal as well as grapefruit and grapefruit products.
| Study group | Role | What they receive |
|---|---|---|
| Ivosidenib | Experimental | -Ivosidenib is an oral drug which will be administered on an outpatient basis at a dose of 500 mg daily for up to 5 years. Each cycle is 28 days. Receives: Drug: Ivosidenib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of improvement in hematologic parameters
Will be evaluated according to a modified version of the IWG 2006 Criteria for Hematologic Improvement for patients with MDS on clinical trials
- Erythroid response (pretreatment, <11 g/DL)
- Hemoglobin (Hgb) increase by ≥1.5 g/dL
- Relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 weeks, compared with the pretreatment transfusion number in the previous 8 weeks. Only RBC transfusions given for an Hgb of ≤9.0 g/dL pretreatment will count in the RBC transfusion response evaluation
- Platelet response (pretreatment, <100 x 10^9/L)
- Absolute increase of ≥30 × 10^9/L for patients starting with >20 × 10^9/L platelets.
- Increase from <20 × 10^9/L to >20 × 10^9/L and by at least 100%.
- Neutrophil response (pretreatment, <1.0 x 10^9/L):
- At least 100% increase and an absolute increase >0.5 × 10^9/L. If pegfilgrastim being used prior to initiation of study, define response as no longer requiring pegfilgrastim to maintain ANC >500.
Measured: Through 30 days after completion of treatment (estimated to be 61 months)
Secondary outcomes (4)
Change in mutant IDH1 variant allele fraction
-ddPCR is a highly sensitive and accurate method for quantifying VAF. This will be performed centrally at the Washington University clinical pathology laboratory using standard procedures. To account for assay variation, the investigators will perform 10 runs using the ddPCR assay and take the mean VAF as the final measurement.
Measured: Through completion of treatment (estimated to be 60 months)
Disease free survival
-Events include development of MDS/AML or death.
Measured: Through 30 days after completion of treatment (estimated to be 61 months)
Number of adverse events as measured by CTCAE v 5.0
Measured: Through 30 days after completion of treatment (estimated to be 61 months)
Duration of hematologic response
Measured: Through completion of treatment (estimated to be 60 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2021
- Study start1 Apr 2022
- Primary completion31 Jan 2030 (estimated)
- Study completion31 Jan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Clonal Cytopenia of Undetermined SignificanceStudies of the same condition, open and under way.
- More trials run by Washington University School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Washington University School of Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- Servier Hellas Pharmaceuticals Ltd., Gateway for Cancer Research
- Responsible party
- Sponsor
- Investigators
- Kelly Bolton, M.D., Ph.D., Principal investigator, Washington University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05030441
- Sponsor's protocol ID
- 202110038
- Status last verified
- Aug 2026
- First submitted
- 24 Aug 2021
- Last updated
- 12 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participate data that underlie the results reported in this article after deidentification (including text, tables, figures and appendices) will be available.